Deep Dive Into Cencora Stock: Analyst Perspectives (6 Ratings)
Portfolio Pulse from Benzinga Insights
Cencora (NYSE:COR) has been analyzed by six analysts, showing a range of sentiments from somewhat bullish to indifferent. The average 12-month price target has increased by 1.4% to $277.67. Analysts have adjusted their ratings and price targets, reflecting their response to recent developments. Cencora is a leading pharmaceutical wholesaler with strong financial performance, including a 10.9% revenue growth rate and a high return on equity. However, it has a high debt-to-equity ratio, indicating financial risk.
September 06, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cencora has received mixed analyst ratings, with a slight increase in the average price target. The company's strong financial performance is offset by a high debt-to-equity ratio, indicating potential financial risk.
The mixed analyst ratings suggest a neutral short-term impact on Cencora's stock price. The increase in the average price target indicates some positive sentiment, but the high debt-to-equity ratio poses a financial risk that could offset potential gains.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100